2004 JUN 7 - (NewsRx.com & NewsRx.net) -- Vyteris, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Vyteris' New Drug Application (NDA) for its LidoSite Topical System.
The system has been approved for use on normal intact skin to provide a local analgesia that numbs the skin prior to the administration of superficial dermatological procedures such as venipuncture, intravenous cannulation, and laser ablation of superficial skin lesions. The product is approved for use on patients aged 5 years and older.
LidoSite uses an active transdermal delivery technology known as iontophoresis, which administers medications through the skin …
No comments:
Post a Comment